The only director selling that has had any notable impact on price was that of JC post CPACS raise (when he was our Chairman, no less). As ex-directors, JC and BG have only ever been 10-15% of free float volume. That free float surged due to RAC incurred clinical delays (some strategic, some not).
The SP has reflected broader holder movements, not that of ex-directors. There was a ~30% collapse in SP in the 2 months AFTER BG ceased selling.
Anyway, I look forward to updating this chart when the next 4C is released. We're already seeing a stark improvement in both shareholders, and share price, all the while JC is selling!
RAC Price at posting:
$1.77 Sentiment: Buy Disclosure: Held
(20min delay)